'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India

Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 inhibitor can deliver long-term value in an ultra-competitive segment.

Can Galvus Deliver Long-Term Value for Cipla? • Source: Shutterstock

Novartis Pharma AG has handed over manufacturing and marketing rights for Galvus, its vildagliptin mother brand and combinations, in India to Cipla Limited , as part of what appears to be a wider portfolio reorientation effort underway at several large foreign firms in the country.

Under the ‘perpetual license agreement’, Cipla will manufacture and market Galvus and Galvus combination brands used to treat type 2...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip